Any clinically relevant biological abnormality found and/or volunteered at screening (other than those related to the disease under investigation) which, in the opinion of the investigator, is clinically significant and would preclude safe participation in this study [e.g., human immunodeficiency virus infection and significant mental illness] Inability to swallow whole tablets Any previous treatment with strontium ranelate or intravenous bisphosphonate Any previous treatment with an oral bisphosphonate as follows: any treatment within the last 6 months; ≥ 1 month cumulative treatment within the last 12 months; ≥ 3 months cumulative treatment within the past 2 years, or ≥ 2 years cumulative treatment within the past 5 years Treatment with fluoride (dose greater than 10mg/day) within the previous 5 years for osteoporosis Treatment with PTH, PTH analogues or similar anabolic agent for osteoporosis within the last 2 years Treatment with other drugs affecting bone metabolism within the last 6 months prior to screening:Chronic systemic corticosteroid (e.g., glucocorticoid, mineralocorticoid) treatment of no more than 2 intra-articular injections within the past year or use of oral, parenteral, or long-term, high-dose inhaled corticosteroids. Treatment with any topical corticosteroid will not exclude the subject from participating; Hormones (e.g., estrogens/"natural estrogen preparations" [except for nonsystemic vaginal treatment], 19-norprogestins, selective estrogen receptor modulators [SERMs] such as raloxifene, anabolic steroids/androgens such as dehydroepiandrosterone [DHEA] or its sulfated form [DHEAS], nandrolone, tibolone, active vitamin D analogs/metabolites that are prescribed for the treatment of osteoporosis or other conditions such as 1,25-dihydroxy vitamin D [calcitriol] or 1-alpha-hydroxyvitamin D3 [1-alpha hydroxycholecalciferol], calcitonin); Calcineurin inhibitors (e.g., cyclosporine, tacrolimus) or methotrexate Contraindications to therapy with calcium or vitamin D Any subject who received treatment with the macrolide antibiotics: clarithromycin, erythromycin, telithromycin, and troleandomycin within 2 days prior to the Baseline visit Administration of any investigational drug within 90 days preceding the first dose of the study medication Current treatment with potent P-glycoprotein and/or potent CYP3A inhibitors is prohibited: Diltiazem and verapamil; any oral azole antifungal (e.g., ketoconazole, itraconazole, fluconazole); Cyclosporine or oral tacrolimus; Ritonavir; Quinidine; Nefazodone Concomitant therapy with proton pump inhibitors (e.g., esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole) is prohibited. Daily, chronic use (>3 doses per week) of histamine-2 receptor antagonists (e.g., cimetidine, famotidine, nizatidine, and ranitidine) is prohibited. Antacids should not be administered within 2 hours (before or after) administration of study medication.